TANOVEA-CA1 Noted in Veterinary Brief Article

dog cancer treatments - veterinary brief

As Sue Ettinger, DVM, DACVIM (Oncology), of Tarrytown, New York, explains in a new article on the Veterinary Brief website, canine lymphoma, one of the most common canine cancers, is actually a collection of cancers arising from the malignant transformation of lymphocytes. Dogs of any age, gender, and breed can be affected with lymphoma, although affected dogs are typically middle-aged to older.

TANOVEA®-CA1 (rabacfosadine for injection), which was conditionally approved by the FDA in December for the treatment of lymphoma in dogs, is a novel cytotoxic agent that is among the newest of dog cancer drugs. As the article points out, TANOVEA-CA1 has demonstrated a reasonable expectation of efficacy and a complete and acceptable safety package. It has produced an overall response rate in clinical studies of 77 percent. More recent studies in dogs with lymphoma have also been conducted and are discussed in the article. 

TANOVEA-CA1 can be used in situations where generic, unapproved chemotherapy treatments have failed or where relapse has occurred. It also can be used in dogs who have been recently diagnosed with lymphoma and have never been treated. Supervision by a veterinarian with expertise in chemotherapy administration is recommended, and standard safety precautions for cytotoxic drugs must be followed when using TANOVEA-CA1.

To read the full article on the Veterinary Brief website from Ettinger, please click here.

Learn More about TANOVEA-CA1

Detailed information about TANOVEA-CA1 (rabacfosadine for injection) can be found at vetdc.com. A list of canine lymphoma veterinary specialists in your area who specialize in new dog cancer treatments is available from our site as well. You can also contact us to learn more about TANOVEA-CA1.